Navigation Links
ivWatch Achieves ISO 13485 Certification: Provides Foundation for International Distribution
Date:8/15/2017

HAMPTON, Va., Aug. 15 2017 /PRNewswire/ -- ivWatch LLC, a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy, today announced receipt of its ISO 13485 Certification, the global standard for medical device quality management systems (QMS) developed by the International Organization for Standardization (ISO®).

ivWatch Model 400 Continuous Monitoring device for the early detection of IV infiltrations.
ivWatch Model 400 Continuous Monitoring device for the early detection of IV infiltrations.

"This is an important milestone for ivWatch, as it validates our commitment to quality and verifies the high standards we follow in the design, development, and manufacturing of the new ivWatch OEM Board and FDA-cleared ivWatch Model 400," says Mike Gahan, vice president of operations at ivWatch. "Obtaining this ISO certification firmly establishes our solid foundation for future growth and we look forward to bringing better, safer IV procedures to more hospitals across the U.S. and around the world." 

To achieve this important certification, ivWatch demonstrated that all of its activities and processes conform to both the ISO® standard and the current good manufacturing practices required by international medical device regulations. The company completed a pre-assessment readiness review, followed by a thorough four-day, stage two audit, conducted by TÜV SÜD, an accredited and internationally-recognized certification body. ivWatch passed this comprehensive stage two audit with zero (0) findings; a major accomplishment for any medical device company.

ivWatch is the leader in developing, commercializing and distributing non-invasive sensor technology to monitor a patient's IV site for complications. The ivWatch Model 400 is an FDA-cleared stand-alone continuous monitoring system that allows clinicians to manage the risk of IVs by providing early detection of infiltration and extravasation. The ivWatch technology is also available to OEMs for integration into existing infusion and patient monitoring products. Reliable early detection of infiltrations and extravasations is a requirement to help hospitals manage the risks associated with this common invasive procedure.

The International Organization for Standardization is the world's largest developer and publisher of international standards for the implementation of quality management systems. EN ISO 13485:2012 + AC:2012 certifies that the ivWatch QMS aligns with the requirements of the Canadian Medical Device Regulations (CMDR), the European Union's Medical Device Directive (MDD) and other regulatory requirements found throughout the world.

ivWatch recent announcements include closing $14.8 million in its latest round of funding and receiving top honors in the 2017 MDEA competition.

About ivWatch

ivWatch LLC is a medical device manufacturer focused on improving patient safety and the effectiveness of intravenous therapy. ivWatch provides a first-of-its-kind, FDA-cleared, noninvasive medical device that continuously monitors peripheral IVs for infiltration and extravasation events. The ivWatch Model 400 aims to help eliminate patient harm associated with adverse events and to reduce drug delivery errors. The ivWatch OEM Board integrates ivWatch technology into existing products, enabling OEMs to help healthcare providers deliver a higher level of patient care and to reduce risks related to IV therapy. The ivWatch OEM Board is not an FDA-cleared device. It is the responsibility of the Original Equipment Manufacturer integrating ivWatch technology to secure the proper regulatory clearance. Follow us on Twitter@ivWatch or Facebook @ivWatchLLC. www.ivWatch.com

MEDIA CONTACT:
Leah Moore
leah.moore@ivwatch.com
Office (855) 489-2824 x7031
Mobile (757) 839-5653

View original content with multimedia:http://www.prnewswire.com/news-releases/ivwatch-achieves-iso-13485-certification-provides-foundation-for-international-distribution-300504327.html


'/>"/>
SOURCE ivWatch, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. DO-HEALTH a multi-center clinical trial on healthy ageing achieves first milestone
2. UCI achieves rare trifecta: 3 scientists receive New Innovator Awards
3. Bruin Biometrics, LLC Achieves Significant Milestone with Receipt of ISO 13485 Certification
4. OU research team achieves $4.5 million Defense grant
5. ​NTU spin-off achieves breakthrough with innovative multifunction membranes
6. Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers
7. NuData Security Achieves Significant Milestones, Furthers Commitment to Providing Unparalleled Online Fraud Detection
8. MedNet Solutions Achieves Record Growth In 2015
9. HYPR IoT Authentication Platform Achieves FIDO Alliance Certification
10. Bruin Biometrics, LLC bereikt significante mijlpaal door behalen van ISO 13485-certificering
11. Bruin Biometrics, LLC erreicht wichtigen Meilenstein mit Zertifizierung nach ISO 13485
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2019)... ... January 31, 2019 , ... Through its ... microbiome research support in study design, planning, sample collection, and analysis to researchers ... and Gynecology, and Dr. Sara Vaughn, MD, Reproductive Endocrinology and Infertility Fellow, to ...
(Date:1/25/2019)... ... 2019 , ... GrowthZone, Inc., provider of association ... indicates membership growth in some sectors and decreasing membership among others. , The ... over 500 association professionals across North America. , “This year’s survey shed ...
(Date:1/20/2019)... ... January 16, 2019 , ... uBiome, the ... research platform that uses artificial intelligence (AI) and a data-centric approach to decentralize ... and ulcerative colitis. , People will Crohn’s or other chronic medical conditions join ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... 2019 , ... Signature Matrix and Signature Cord are the ... stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and ... tissue allograft that originates from the same tissue used to manufacture the purified, ...
(Date:1/30/2019)... ... January 29, 2019 , ... ... and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites ... $59.1 million backed by multiple global investors lead by China's State Development & ...
(Date:1/30/2019)... ... 29, 2019 , ... K&R Negotiations announced today that Mladen Kresic, CEO and ... titled: Six Ways to Shorten the Sales Cycle : Reduce Complexity and Increase ... BrightTALK network. , Negotiation expert Kresic will discuss the realities of today’s complex ...
(Date:1/30/2019)... ... January 30, 2019 , ... Through its Microbiome Grant ... in study design, planning, sample collection, and analysis to a team of researchers ... to study the interactions between gut microbial composition and cardiovascular health risks, such ...
Breaking Biology Technology: